Cart
sales@molnova.com
Sonrotoclax
CAS No. 2383086-06-2
Sonrotoclax( —— )
Catalog No. M36604 CAS No. 2383086-06-2
Sonrotoclax is a potent, orally active inhibitor of Bcl2, demonstrating effective cell-killing activity against a range of lymphoma and leukemia cell lines .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 391 | In Stock |
|
| 5MG | 264 | In Stock |
|
| 10MG | 398 | In Stock |
|
| 25MG | 605 | In Stock |
|
| 50MG | 886 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSonrotoclax
-
NoteResearch use only, not for human use.
-
Brief DescriptionSonrotoclax is a potent, orally active inhibitor of Bcl2, demonstrating effective cell-killing activity against a range of lymphoma and leukemia cell lines .
-
DescriptionSonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines.
-
In Vitro——
-
In VivoAnimal Model:Female NCG mice with acute lymphoblastic leukemia (ALL) xenografts Dosage:5, 15, 50 mg/kg Administration:oral administration; daily, for 42 days Result:Inhibited tumor growth in a dose-dependent manner.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBCL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2383086-06-2
-
Formula Weight890.1
-
Molecular FormulaC49H59N7O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (112.35 mM; Ultrasonic )
-
SMILESCC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC([N+]([O-])=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1.
molnova catalog
related products
-
A-1331852
A-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM).
-
Lisaftoclax
Bcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.
-
CYD-2-11
CYD-2-11 is a novel potent, selective Bax agonist that targets the structural pocket proximal to S184 in the C-terminal region of Bax (Ki=34.1 nM).
